Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …

Background Immune checkpoint inhibitors have not shown clinical benefit to patients with
metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Colorectal cancer is a prevalent disease worldwide, with more than 50% of patients
developing metastases to the liver. Despite advances in improving resectability, most …

(1) Background: Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …

Colorectal cancer (CRC) has the second highest mortality rate among all cancers
worldwide. Surgery, chemotherapy, radiotherapy, molecular targeting and other treatment …

Importance Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable
(MSS) or mismatch repair–proficient (pMMR) colorectal cancer. Recent findings suggest the …

PURPOSE To verify whether the intensification of the upfront chemotherapy backbone with a
modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan …